Our results to date suggest that Vaxil’s SP based antigens may act as neoantigens, thereby eliciting a robust and specific immune response. Unlike mutated epitopes in “classical” neoantigens, these SP domains are native sequences that may exist on multiple cancer types in various populations, thereby making this a potential universal vaccination strategy.
VAXIL – Creating the ideal immunotherapy
Inducing a Broad
Cancer ResistanceLearn More
Immune ResponseLearn More
Cancer Stem CellsLearn More
First Ever SP-Specific
Antibody PlatformLearn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.